[2] [2] Dalzell JR. Review of cardiogenic shock after acute myocardial infarction[J]. JAMA, 2022, 327(9): 878.

[6] [6] Shah AH, Puri R, Kalra A. Management of cardiogenic shock complicating acute myocardial infarction: a review[J]. Clin Cardiol, 2019, 42(4): 484-493.

[7] [7] Davodian LW, Larsen JKP, Povlsen AL, et al. Timing and causes of death in acute myocardial infarction complicated by cardiogenic shock (from the RETROSHOCK cohort)[J]. Am J Cardiol, 2022, 171: 15-22.

[9] [9] Wang JY, Shen BT, Feng XX, et al. A review of prognosis model associated with cardiogenic shock after acute myocardial infarction[J]. Front Cardiovasc Med, 2021, 8: 754303.

[14] [14] Kanic V, Kompara G. Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock[J]. Front Cardiovasc Med, 2024, 10: 1266127.

[19] [19] Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock[J]. Circulation, 2019, 139(10): 1249-1258.

[20] [20] Khalid N, Ahmad SA. Impact of timing of impella support in patients with acute myocardial infarction complicated by cardiogenic shock[J]. Cardiovasc Revasc Med, 2022, 39: 36-37.

[21] [21] Tariq MD, Jain H, Khan AM, et al. Efficacy and safety of percutaneous mechanical circulatory support in patients with cardiogenic shock following acute myocardial infarction: a meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2024, 103(46): e40595.

[22] [22] Elsaeidy AS, Taha AM, Abuelazm M, et al. Efficacy and safety of extracorporeal membrane oxygenation for cardiogenic shock complicating myocardial infarction: a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2024, 24(1): 362.

[28] [28] Lambert LJ, Sas G, Dragieva N, et al. Characteristics of patients with coronary artery disease treated with multivessel percutaneous coronary intervention in hospitals with and without on-site cardiac surgery in qubec: a province-wide field evaluation[J]. Can J Cardiol, 2014, 30(10): S147-S148.

[29] [29] Kujiraoka H, Tsuchiyama T, Inagaki D, et al. Comparison of the efficacy of excimer laser coronary angioplasty for ST-segment elevation myocardial infarction with onset-to-balloon time[J]. Lasers Med Sci, 2023, 38(1): 126.

[30] [30] Shimojo K, Shibata N, Takagi K, et al. Excimer laser coronary angioplasty versus manual aspiration thrombectomy in patients with ST-segment elevation myocardial infarction: analyzed by nuclear scintigraphy[J]. Int J Cardiovasc Imaging, 2023, 39(4): 831-842.

[31] [31] Jang WJ, Park IH, Oh JH, et al. Efficacy and safety of durable versus biodegradable polymer drug-eluting stents in patients with acute myocardial infarction complicated by cardiogenic shock[J]. Sci Rep, 2024, 14(1): 6301.

[32] [32] Wan YD, Wang DY, Deng WQ, et al. Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: a systematic review and meta-analysis[J]. Front Cardiovasc Med, 2022, 9: 949494.

[33] [33] Zhang YX, Chen DL, Dong QC, et al. Drug-coated balloons for acute myocardial infarction: a meta analysis of randomized clinical trials[J]. J Interv Cardiol, 2022, 2022: 4018771.

[34] [34] Geng BY, Liu Z, Feng GZ, et al. Drug-coated balloon versus drug-eluting stent in acute myocardial infarction: a protocol for systematic review and meta-analysis[J]. Medicine (Baltimore), 2021, 100(44): e27259.

[35] [35] Hu HL, Shen L. Drug-coated balloons in the treatment of acute myocardial infarction (review)[J]. Exp Ther Med, 2021, 21(5): 464.

[36] [36] Zhang QT, Xu LZ, Xie ZY, et al. Machine learning-based prediction of mortality in acute myocardial infarction with cardiogenic shock[J]. Front Cardiovasc Med, 2024, 11: 1402503.

[37] [37] Rivas-Lasarte M, Sans-Rosell J, Collado-Lled E, et al. External validation and comparison of the CardShock and IABP-SHOCK Ⅱ risk scores in real-world cardiogenic shock patients[J]. Eur Heart J Acute Cardiovasc Care, 2021, 10(1): 16-24.

[38] [38] Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021[J]. J Am Coll Cardiol, 2022, 79(9): 933-946.